Synergy Pharmaceuticals Inc Fl (NASDAQ:SGYP)

CAPS Rating: 2 out of 5

Recs

5
Player Avatar DarthMaul09 (29.74) Submitted: 10/14/2009 2:14:31 AM : Underperform Start Price: $4.05 SGYP Score: +29.77

Synergy Pharmaceuticals, Inc. (Synergy) is a development-stage biopharmaceutical company. The Company primarily focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Synergy’s lead drug candidates, acquired from Synergy-DE comprise: SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C) and SP-333, a second generation GC-C receptor analog, which is in the pre-clinical development for the treatment of ulcerative colitis (UC).

UC is the most important medical problem that they are designing drugs for, but they are only in the "pre-clinical development" stage, which means they have a long way to go before having a marketable drug. If they are bought out by a big pharma company or are able to lease a discovery, then they could justify a speculative bet, but limited reimbursement for new medications and difficulty with the FDA makes profitable success less likely.

Featured Broker Partners


Advertisement